A startup developing a drug discovery platform capable of simultaneously measuring intracellular signals over time using proprietary technology, addressing multi-factor and multi-target drug discovery. Accelerating efficient and comprehensive new drug development through high-dimensional data and AI analysis.
We are a company that researches, develops, manufactures, and sells glycoconjugates, such as glycoproteins and glycopeptides. The development of ADCs using glycan linkers is progressing in the pharmaceutical industry, and we are capable of conducting basic research and contract-based research on these products as well as supplying large quantities of API raw materials. We are also conducting new research and development using glycans, including in mRNA vaccines and other macromolecular LNPs. Our in-house glycosylated somatostatin is currently undergoing clinical trials (Phase 2a), and we plan to out-license the technology in the future.
Bioaccell is a Kyoto-based contract cell processing company that cultivates therapeutic immune cells for medical institutions. It provides certified cell culture services for cancer immunotherapy.
Development of technology for assessing micronutrient intake using hair and provision of analysis services.
We are developing generative AI to support decision-making for healthcare professionals and the general public. Specifically, Cubec functions as a learning support tool that answers questions arising in physicians’ daily practice, and it generates revenue by providing pharmaceutical companies with high-precision data on physician needs. We are planning a phased business rollout, with the ultimate goal of implementing as a Software as a Medical Device (SaMD) that supports physicians’ clinical decision-making.